Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 16/20 | 0.44 |
| ▸ | NQO2 | P16083 | 3/20 | 0.42 |
| ▸ | NQO1 | P15559 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
| ▸ | HTR1F | P30939 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2002520 | 0.89 | HTR6 (0.44) | HTR6NQO2NQO1HTR1ADRD2 | |
| SCHEMBL2010180 | 0.87 | HTR6 (0.56) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL2007319 | 0.87 | KCNH2 (0.62) | KCNH2HTR6NQO2CYP3A4CYP2D6 | |
| SCHEMBL2010374 | 0.82 | HTR6 (0.44) | HTR6NQO2NQO1 | |
| SCHEMBL2007642 | 0.81 | KCNH2 (0.60) | KCNH2HTR6CYP3A4CYP2D6HTR1A | |
| SCHEMBL2314508 | 0.81 | HTR6 (0.42) | KCNH2HTR6NQO2NQO1HTR1A | |
| SCHEMBL2007279 | 0.79 | HTR6 (0.47) | KCNH2HTR6CYP3A4CYP2D6HTR1A | |
| SCHEMBL2006196 | 0.78 | HTR6 (0.57) | HTR6NQO2HTR1ADRD2HTR1D | |
| SCHEMBL2008761 | 0.77 | HTR6 (0.44) | KCNH2HTR6NQO2NQO1CYP3A4 | |
| SCHEMBL2006044 | 0.76 | HTR6 (0.55) | KCNH2HTR6NQO2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200980-B9 | AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS FIELD OF INVENTION | SUVEN LIFE SCIENCES LTD (IN) | 2011-12-28 | — | — | EP | claimed |
| EP-2200980-B1 | AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS FIELD OF INVENTION | SUVEN LIFE SCIENCES LTD (IN) | 2011-08-03 | — | — | EP | claimed |
| US-7964627-B2 | Amino arylsulfonamide compounds and their use as 5-HT6 ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | claimed |
| US-20100216861-A1 | AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-08-26 | — | — | US | claimed |
| EP-2200980-B9 | AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS FIELD OF INVENTION | SUVEN LIFE SCIENCES LTD (IN) | 2011-12-28 | — | — | EP | disclosed |
| EP-2200980-B1 | AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS FIELD OF INVENTION | SUVEN LIFE SCIENCES LTD (IN) | 2011-08-03 | — | — | EP | disclosed |
| US-7964627-B2 | Amino arylsulfonamide compounds and their use as 5-HT6 ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | disclosed |
| US-20100216861-A1 | AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216861-A1 | AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | HTR6, HTR5A, HTR1A | KCNH2 1645/4885HTR6 1/4885NQO2 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.